Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments
Ocugen remains a "Buy", driven by pivotal phase 2/3 GARDian3 trial progress for OCU410ST in Stargardt Disease. FDA and EMA regulatory alignment enables a single U.S. trial to support both BLA and MAA filings for OCU410ST, expediting potential approvals. Interim data from GARDian3 is expected by mid-2026, with possible BLA submission for OCU410ST in 2027 if results are positive.
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript
Ocugen, Inc. ( OCGN ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Tiffany Hamilton - AVP & Head of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Boris Peaker Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Elemer Piros - Lucid Capital Markets, LLC, Research Division Daniil Gataulin - Chardan Capital Markets, LLC, Research Division Presentation Operator Good morning, and welcome to Ocugen's Third Quarter 2025 Financial Results and Business Update.
Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.05 per share a year ago.
Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know
Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Ocugen, Inc. (NASDAQ:OCGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Huma Qamar - Chief Medical Officer Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Shankar Musunuri - Co-Founder, CEO & Chairman Tiffany J. Hamilton - AVP & Head of Corporate Communications Conference Call Participants Boris Peaker - Unidentified Company Daniil V.
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago.
Ocugen: Three Potential Gene-Therapy Filings By 2028
Ocugen's OCU400 Phase 3 plus Korean licensing underpin potential 2026 BLA remains the company's best bet at its first commercial gene therapy revenue. OCU410ST also received a Rare Pediatric Disease status and now heads towards a pivotal Phase 2/3 trial. Its potential approval would also give OCGN a valuable PRV. OCU410 has shown promising early vision-gain and lesion-slow data, which could be a third BLA target by 2028.
Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript
Call Start: 8:30 January 1, 0000 8:59 AM ET Ocugen, Inc. (NASDAQ:OCGN ) Q1 2025 - Earnings Conference Call May 9, 2025, 8:00 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Arun Upadhyay - Chief Scientific Office Conference Call Participants Michael Okunewitch - Maxim Group Robert LeBoyer - Noble Swayampakula Ramakanth - H.C. Wainwright Operator Good morning, and welcome to Ocugen's First Quarter 2025 financial results and business update.
Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript
Ocugen, Inc. (NASDAQ:OCGN ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group Swayampakula Ramakanth - H.C. Wainwright Robert LeBoyer - Noble Capital Markets Daniil Gataulin - Chardan Operator Good morning, and welcome to Ocugen's Fourth Quarter and Full Year 2024 Financial Results and Business Update.
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
